000			03791cam a2200829 a 4500
001			ocn811850420
003			OCoLC
005			20171113131232.0
006			m o d
007			cr |||||||||||
008			121002s2013 nju ob 001 0 eng
010			_a 2012040270
020			_a9781118354582 _q(epub)
020			_a1118354583 _q(epub)
020			_a9781118354575 _q(pdf)
020			_a1118354575 _q(pdf)
020			_a9781118354568 _q(mobi)
020			_a1118354567 _q(mobi)
020			_a9781118354599 _q(electronic bk.)
020			_a1118354591 _q(electronic bk.)
020			_a9781299241954 _q(MyiLibrary)
020			_a1299241956 _q(MyiLibrary)
020			_z9780470646274 _q(cloth)
020			_z0470646276 _q(cloth)
029	1		_aAU@ _b000050086446
029	1		_aCHBIS _b009914530
029	1		_aCHVBK _b175204659
029	1		_aDKDLA _b820120-katalog:000655910
029	1		_aNLGGC _b356864928
029	1		_aNZ1 _b15340367
029	1		_aNZ1 _b15905471
029	1		_aDEBBG _bBV043395079
035			_a(OCoLC)811850420 _z(OCoLC)828793860 _z(OCoLC)961568624 _z(OCoLC)962707379 _z(OCoLC)966257693
040			_aDLC _beng _epn _cDLC _dYDX _dDG1 _dN$T _dYDXCP _dE7B _dCDX _dIDEBK _dCOO _dNOC _dOCLCF _dCCO _dNLGGC _dRECBK _dEBLCP _dOCLCQ _dOCLCO _dD6H _dLOA
042			_apcc
049			_aMAIN
050	0	0	_aRM301.4 _b.F87 2013
060	1	0	_aQU 450
072		7	_aMED _x071000 _2bisacsh
082	0	0	_a615.7 _223
245	0	0	_aFusion protein technologies for biopharmaceuticals : applications and challenges / _cedited by Stefan R. Schmidt. _h[electronic resource]
260			_aHoboken, New Jersey : _bJohn Wiley & Sons, _c©2013.
300			_a1 online resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
504			_aIncludes bibliographical references and index.
505	0		_apt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
520			_aThe state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei.
588	0		_aPrint version record and CIP data provided by publisher.
650		0	_aBiopharmaceutics.
650		0	_aPharmaceutical biotechnology.
650		4	_aDrug carriers.
650		4	_aImmunotoxins _xTherapeutic use.
650		4	_aProtein engineering.
650		4	_aRecombinant fusion proteins _xTherapeutic use.
650		7	_aMEDICAL _xPharmacology. _2bisacsh
650		7	_aBiopharmaceutics. _2fast _0(OCoLC)fst00832650
650		7	_aPharmaceutical biotechnology. _2fast _0(OCoLC)fst01060106
650		2	_aRecombinant Fusion Proteins _xtherapeutic use.
650		2	_aDrug Carriers.
650		2	_aImmunotoxins _xpharmacokinetics.
650		2	_aImmunotoxins _xtherapeutic use.
650		2	_aProtein Engineering.
650		2	_aRecombinant Fusion Proteins _xpharmacokinetics.
655		4	_aElectronic books.
655		7	_aElectronic books. _2local
700	1		_aSchmidt, Stefan R.
776	0	8	_iPrint version: _tFusion protein technologies for biopharmaceuticals. _dHoboken, N.J. : John Wiley & Sons, ©2013 _z9780470646274 _w(DLC) 2012039440
856	4	0	_uhttp://onlinelibrary.wiley.com/book/10.1002/9781118354599 _zWiley Online Library
942			_2ddc _cBK
999			_c206191 _d206191